Purpose Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers. Concurrent radiochemotherapy is the standard of care for advanced tumors. However, there is a need for more efficient regimens with less side effects resulting from high doses. Therefore, we set out to explore the therapeutic potential of ternary combinations by bringing together irradiation, cis-platinum and a TLR3 agonist, poly(I:C), with the aim to reduce the dosage of each treatment. This approach is based on our previous work, which revealed a selective cytotoxic effect of TLR3 agonists against malignant cells when combined with other anti-neoplastic agents. Methods We explored the survival of HNSCC-derived cells (Detroit 562, FaDu, SQ20B and Cal27) using MTT and caspase 3/7 activation assays. The radio-sensitization effects of poly(I:C) and cisplatin were assessed using Western blotting, cell cycle progression, ROS formation and qRT-PCR assays. Results We found that the combination of poly(I:C) and cisplatin downregulated c-IAP2 and survivin expression, reduced cell survival, induced anti-apoptotic gene expression and apoptosis, increased ROS formation and induced G2/M cell cycle arrest in the HNSCC-derived cells tested. Conclusions Our results indicate that a combined poly(I:C) and cisplatin treatment reduces the survival and induces the radiosensitivity of HNSCC-derived cells, thus providing a rationale for the development of novel strategies for the treatment of head and neck cancer.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is the 6th most frequent cancer worldwide [1] . The most common etiological factors include consumption of tobacco and alcohol and infection with human papilloma virus (HPV, for oropharyngeal cancer) [2] [3] [4] . The therapeutic approaches may vary depending on the location, stage and pathohistological properties of the disease, but commonly include surgery, radiotherapy, chemotherapy and targeted therapy with cetuximab [5] . The combination of radiotherapy and cisplatin-based chemotherapy is the standard therapeutic approach for the treatment of high-risk, locally advanced HNSCC [6] . Cis-platinum brings a double benefit: it acts as a radio-sensitizer for the tumor mass and contributes to the control of distant micro-metastases.
However, chemo-radiotherapy is associated with notable toxicity, especially when used in a concurrent setting and in higher doses, which is often necessary for the treatment of advanced tumors [7] . Hence, there is a need for novel therapeutic approaches to increase the therapeutic index.
Toll-like receptors (TLRs) are transmembrane patternrecognition receptors that are expressed on the surface of antigen-presenting cells (APCs), such as dendritic cells (DCs) and macrophages, where they recognize pathogen-associated molecular patterns, or PAMPs [8, 9] . Once the ligand binds to the receptor, a signaling cascade is initiated, resulting in activation of NF-κB transcription factors, as well as members of the AP-1 and IRF family, finally leading to the secretion of interferons, cytokines and chemokines [10] . TLRs have also been found to be expressed in tumor tissues, including head and neck cancer tissues [11, 12] . TLR3 is mainly expressed in the endosome, where it recognizes double-stranded RNA [13] or polyinosinic:polycytidylic acid (poly(I:C)), a synthetic dsRNA analog. Several studies have reported TLR3 expression in HNSCC cells [14, 15] . The effects of TLR3 agonists, especially poly(I:C), on malignant epithelial cells has so far remained controversial. Some studies have reported proapoptotic effects of TLR3 agonists, but these effects were generally obtained using very high agonist concentrations not compatible with clinical use [16, 17] . Other studies dealing with low agonist concentrations showed evidence for a contribution to carcinogenesis and the promotion of tumor growth and invasiveness [18, 19] . We have previously shown that these protumorigenic effects result at least in part from overexpression of the cellular Inhibitor of Apoptosis Protein 2 (c-IAP2). Combining TLR3 agonists with agents inhibiting c-IAP2 not only led to inhibition of their pro-tumorigenic effects, but also unmasked strong pro-apoptotic effects [20] [21] [22] . Because c-IAP2 inhibitors are not yet in clinical use, we decided to investigate whether it is possible to create a similar type of synergy with other anti-neoplastic agents like cis-platinum.
In our current study we show that the combination of poly(I:C) and cisplatin increases the sensitivity of malignant HNSCC cells to irradiation. In addition, we present indications for the mechanism underlying this radio-sensitization effect.
Materials and methods

Cells and reagents
The human HNSCC-derived cell lines SQ20B, FaDu and Detroit 562 were maintained in Dulbecco's modified Eagle medium (DMEM, Life technologies, Gaithersburg, USA) supplemented with 2 mM L-glutamine and 10% fetal calf serum (FCS) in a humidified chamber at 37°C in 5% CO 2 . The Detroit 562 cell line was obtained from the EACC, whereas the Fadu and SQ20B cell lines were provided by Prof. Eric Deutsch (Gustave Roussy, Villejuif, France). Poly(I:C) and polyadenylicpolyuridylic acid (poly(A:U)) were obtained from InvivoGen (San Diego, USA). Doxycyclin was purchased from Sigma Aldrich. Details on the inhibitor of apoptosis (IAP) mimetic RMT5265 have been decribed previously [16] . The compound was kindly provided by Xiaodong Wang (Dallas, USA). Subclones of the SQ20B and FaDu cell lines were established by transfection with a plasmid carrying a shRNA directed against TLR3 and a doxycycline inducible promoter (TET-on system), thus allowing conditional knock-down of TLR3 as described previously [18] .
Proliferation assay
Proliferation assessments were carried out using a MTT Cell Proliferation Assay, which is a colorimetric assay that measures the reduction of a tetrazolium component (MTT) into an insoluble formazan product by mitochondria of viable cells. The absorbance (OD, optical density) was measured at 570 nm using a microplate reader. This absorbance is directly proportional to cell viability. Cells were seeded at a density of 1 × 10 4 cells/well in a 96-well plate and treated with poly(I:C) (10 μg/ml), poly(A:U) (10 μg/ml) and cisplatin (1 μM) for 45 min followed by irradiation. The MTT test was performed after 72 h. Each measurement was performed in quadruplicate in three individual experiments.
Irradiation
For gamma irradiation, the cells were exposed to a 60 Co γ-irradiation panoramic source (20 mGy/s; Rudjer Boskovic Institute, Radiation Chemistry and Dosimetry Laboratory) to in total 2.5 Gy or 7.5 Gy.
RNA isolation and quantitative real time PCR
Twenty four hours after treatment of the cells with poly(I:C), cisplatin and irradiation for 45 min, RNA was isolated using a RNeasy Mini Kit (Qiagen, Hilden, Germany). Next, 0.1 μg total RNA was used as a template for cDNA synthesis using a TaqMan ® Reverse Transcription Reagens Kit (Applied Biosystems, Branchburg, USA). Subsequent PCR reactions were performed using a Sybr® Green PCR Master Mix (Applied Biosystems, Warrington, UK) in conjunction with a CFX96™ Real-Time PCR Detection System (BioRad, USA).The primer sequences used are shown in the Supplementary data. The following amplification program was used: 95°C for 10 min (initial denaturation), 95°C for 30 s (denaturation), 62°C for 30 s and 60°C for 30 s (annealing and elongation). The resulting data were normalized to 28S rRNA. All data were analyzed using the 2-ΔΔCt (relative quantitation) method, after ensuring that all primer sets amplified their respective target sequences with similar efficiencies without the formation of primer-dimers.
Caspase 3/7 enzyme activity measurement
Caspase 3/7 enzyme activity was determined using a Caspase-Glo 3/7 assay kit (Promega, Madison, USA) as previously described [17] . Briefly, SQ20B cells were seeded at a concentration of 1.5 × 10 4 cells/well in a whitewalled 96-well plate in 100 μl culture medium and treated with 10 μg/ml poly(I:C) or 1 μM cisplatin for 45 min and irradiated (see above). After 24 h, caspase 3/7 activity was determined. To this end, 80 μl Caspase-Glo 3/7 reagent was added to each well after which the plate was incubated at room temperature for 1 h. Finally, the luminescence of each sample was measured using a luminometer (Fluoroscan ascent FL, Thermo Sientific, Germany).
Western blot analysis
Cells were seeded in 6-well plates at a density of 0.4 × 10 6 / well. Twenty four hours after treatment of the cells with poly(I:C), cisplatin and irradiation for 45 min, proteins were isolated through resuspension of the cells in RIPA buffer containing a protease inhibitor cocktail (Complete Mini EDTA-free, Roche.) and subsequent sonication. Next, 4× Laemmly buffer (0.25 M Tris-HCl pH 6.8, 20% DTT, 8% Na dodecyl sulfate, 40% glycerol, 0.008% bromophenol blue) was added to obtain a 1× mixture after which the samples were heated to 95°C. For Western blot analysis equal amounts of protein (40 μg) were separated through 10% or 12% SDS-PAGE and transferred to 0.2 μm nitrocellulose membranes (BioRad). The membranes were blocked with 5% nonfat dry milk and subsequently incubated with the following primary antibodies: anti-IAP (Family Antibody Sampler Kit #9770, Cell Signaling Technology), anti-PARP (Calbiochem) and anti-β-actin (Sigma-Aldrich). Next,the membranes were incubated with a peroxidase conjugated secondary antibody (NA934V, Amersham, 1:3000) and protein bands were visualized using a chemiluminescent system (Perkin Elmer). Densitometric calculations of the protein band intensities were performed using a Uvidoc Cambridge Chemiluminescence Imaging system in conjunction with UVIband software (Uvitec, Cambridge, UK).
Intracellular ROS production measurement
Cells were seeded at a density of 2 × 10 4 cells/well in a 96-well white-walled plate. After washing with Hanks Balanced Salt Solution (HBSS), the cells were incubated for 30 min with a non-fluorescent dye 2′,7′-dichlorofluorescein diacetate (DCFH-DA, Fluka) for intracellular ROS detection. This cellpermeable dye remains non-fluorescent inside the cell until the acetate groups are removed by intracellular esterases and oxidized by intracellular ROS to form the fluorescent compound 2′,7′-dichlorofluorescein (DCF). This compound can be used for the sensitive and rapid quantitative determination of intracellular ROS production in response to oxidative stress. After incubation with DCFH-DA, the cells were treated with 1 μM cisplatin and 10 μg/ml poly(I:C) in HBSS, and after 2 h the fluorescence intensity was measured using an Infinite® 200 PRO microplate reader (Tecan) with excitation at 500 nm and emission detection at 529 nm.
Cell cycle analysis
Detroit 562 cells were seeded in 12-well plates and treated with 10 μg/ml poly(I:C) and 1 μM cisplatin for 45 min and irradiated (see above). After 24 or 72 h, the cells were harvested, washed, fixed in ice-cold 70% ethanol, treated with RNAse and stained with propidium iodide (PI, SigmaAldrich) to assess cell cycle distributions. 15.000 events were counted for each experimental setup using routine flow cytometric analyses (FACSCalibur™, Becton-Dickinson, Heidelberg, Germany). Histograms were created and analyzed using ModFit software (Verity Software House, Topsham, ME, USA). For validation, each experiment was repeated at least three times on different days.
Statistics
Statistical significance was assessed using two-tailed Student's t test, and the results are given as the mean ± SD. p values < 0.05 were considered statistically significant.
Results
Poly(I:C) and cisplatin in combination with irradiation reduce HNSCC cell survival
First, we set out to determine whether poly(I:C) in combination with cisplatin may increase radio-sensitivity in HNSCC cells, especially SQ20B cells, which are known to be radioresistant. We found that in Detroit 562 cells poly(I:C) alone induced cell death up to 90%, which was further increased to 100% when the cells were irradiated after the pretreatment with poly(I:C) (Fig. 1a) . We also found that a combined poly(I:C) and cisplatin pre-treatment showed similar results as poly(I:C) alone. Poly(I:C) treatment of SQ20B cells reduced their survival to 30%, which was slightly further reduced by the subsequent addition of cisplatin. Irradiation of SQ20B cells with 2.5 Gy after poly(I:C) treatment did not show any change in cell survival, however irradiation with a 7.5 Gy dose after poly(I:C) pre-treatment led to a statistically significant reduction in cell survival (Fig. 1b) .
Combinational pre-treatment with poly(I:C) and cisplatin showed a statistically significant reduction in cell survival only after irradiation with 7.5 Gy compared to poly(I:C) pretreatment alone. All of the poly(I:C)-related pre-treatment effects were abolished in shTLR3 transfected cells induced by doxycycline, which was statistically significant in all experiments except in the poly(I:C) and cisplatin without irradiation experiment, but even there the trend was noticeable. These data indicate that the observed effects are TLR3 dependent. We found that the FaDu cells were less sensitive to 10 μg/ml poly(I:C) than the Detroit 562 and SQ20B cells, with a more than 50% survival after this treatment (Fig. 1c) . Additional irradiation did not affect the survival of these cells, even at a 7.5 Gy dose.
Poly(I:C) and cisplatin downregulate c-IAP2 and reduce HNSCC cell survival
After we found that poly(I:C) also induced an increase in c-IAP2 expression in Detroit 562 cells, which could be abolished by the addition of cisplatin (Fig. 2a) , we found that other chemotherapeutics, such as hydroxyurea and methotrexate, did not show this phenomenon. Cleaved PARP expression was also found to be highest in samples treated with poly(I:C) and cisplatin. We also treated the cells with different concentrations of the IAP inhibitor RMT5265 and found that even the lowest concentration (10 nM) was enough to decrease Detroit 562 cell survival in combination with 10 μg/ml poly(I:C) (Fig. 2b) . Poly(A:U), which is a more selective Fig. 1 Survival of HNSCC cells after treatment with poly(I:C) (10 μg/ml), poly(A:U) (10 μg/ml) and cisplatin (1 μM) for 45 min followed by irradiation: Detroit 562 (a), SQ20B (b) and FaDu (c) cells. pIC-poly(I:C), pAU-poly(A:U), cisPt-cisplatin, sh control+dox-cells transfected with control plasmid and induced by doxycyline, shTLR3+ dox-cells transfected with TLR3 plasmid and induced by doxycycline. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001 TLR3 ligand, did not induce any statistically significant cell death, but when combining poly(A:U) with a higher concentration of IAP inhibitor (200 nM) we observed a reduced cell survival of 40%. This means that other dsRNA receptors, such as MDA5 and RIG-I, are involved in poly(I:C)-mediated cell death induction. Subsequent proliferation assays of Detroit 562 cells treated with different chemotherapeutic agents, poly(I:C) and IAP inhibitor revealed that cisplatin in combination with poly(I:C) led to the lowest cell survival, which was slightly increased by the addition of IAP inhibitor, suggesting that other anti-apoptotic proteins may be involved (Fig. 2c) . Since cisplatin and the IAP inhibitor used showed similar effects in Detroit 562 cells with respect to c-IAP2 expression and cell survival reduction, we sought to further explore this phenomenon in different HNSCC cells, especially SQ20B cells because they are radioresistant. In our subsequent experiments we used cisplatin, as it is already used in clinical practice. Since we found that FaDu cells did not show any significant response to poly(I:C) and cisplatin followed by irradiation, we excluded them from the next experiments. First, we aimed to determine whether poly(I:C) and cisplatin induce the expression of pro-apoptotic and/or anti-apoptotic genes and whether this expression changes after irradiation. We found that the expression of BAD, which is a proapoptotic gene, was not significantly induced after poly(I:C) or combined poly(I:C) and cisplatin treatment. We did find, however, that poly(I:C) and cisplatin treatment in combination with irradiation doubled its expression in SQ20B cells. Interestingly, we found that poly(I:C), cisplatin and irradiation in these cells, in which TLR3 is inhibited, increased its expression up to 5 times (Fig. 3a) . Poly(I:C) treatment alone or in combination with cisplatin decreased the expression of another pro-apoptotic gene, PUMA, in SQ20B cells. A similar observation was made in SQ20B cells pre-treated with poly(I:C) followed by irradiation. The expression of the anti-apoptotic gene survivin was found to be increased after poly(I:C) and combined poly(I:C) and cisplatin treatment, as well as after poly(I:C) treatment followed by irradiation. In case of poly(I:C) treatment and irradiation, its expression reduction by TLR3 inhibition was found to be statistically significant. The expression of DIABLO, a proapoptotic gene, was found to be increased in a statistically significant manner only after pre-treatment of the SQ20B cells with poly(I:C) followed by irradiation. Interestingly, we found that inhibition of TLR3 in combination with poly(I:C), cisplatin and irradiation increased the expression of DIABLO up to 4 times. We also found, however, that irradiation alone increased the expression of DIABLO in cells in which TLR3 was inhibited, so this might be a consequence of irradiation. We also assessed the expression of the BAD, BAX and BCL-XL genes, but neither of them showed any statistically significant change (data not shown). In Cal27 cells, however, we obtained different results. We found that the PUMA gene was upregulated in a statistically significant manner after all treatments, i.e., after poly(I:C) treatment alone, after combined poly(I:C) and cisplatin treatment, after poly(I:C) treatment followed by irradiation and after combined poly(I:C) and cisplatin treatment followed by irradiation where, in the latter case, its expression was highest. We found that the expression of survivin and DIABLO was decreased after poly(I:C) treatment alone followed by irradiation and after cisplatin treatment alone followed by irradiation (Fig. 3b) . In Detroit 562 cells the expression of PUMA was found to be similar to that in Cal27 cells. The expression of survivin was also downregulated after poly(I:C) treatment (Fig. 3c) .
Expression of IAP family proteins after poly(I:C), cisplatin and irradiation
We found that the expression of survivin was increased after poly(I:C) treatment in SQ20B and decreased again after the addition of cisplatin (Fig. 4a) , but that this effect was not TLR3 dependent. In contrast, we found that in Detroit 562 cells the expression of survivin and c-IAP2 increased after poly(I:C) treatment and that this increase was abolished by the addition of cisplatin (Fig. 4b) . We also found that the increased survivin expression in Detroit 562 cells was MEK dependent (Fig. 4c) .
Poly(I:C) and cisplatin treatment of SQ20B cells increases apoptosis and ROS formation
To explore the mechanism(s) underlying the observed cytotoxic and radio-sensitizing effects of poly(I:C) and cisplatin in radioresistant SQ20B cells, we set out to measure caspase 3/7 activities. We found that poly(I:C) alone can increase the caspase 3/7 activity of SQ20B cells by almost two-fold, and that the addition of cisplatin increased the apoptotic rate to exactly 200% compared to that in untreated cells (Fig. 5a) . Inhibition of TLR3 led to a 40-60% reduction in apoptotic rate. We also found, however, that subsequent irradiation did not increase the observed effects, i.e., the results obtained with irradiated cells were similar to those of non-irradiated cells. We also decided to determine ROS formation after poly(I:C) and cisplatin treatment to see whether this is the mechanism by which the HNSCC cells can become radiosensitive. We found that ROS formation was increased by 30% after poly(I:C) treatment and that combined poly(I:C) and cisplatin treatment resulted in only a slight increase in ROS formation (Fig. 5b) . We also found that the poly(I:C)-induced ROS formation was TLR3-dependent while that of the poly(I:C) and cisplatin combination was not, but this is probably due to increased ROS formation after cisplatin alone treatment.
Poly(I:C) and cisplatin treatment cause G2/M cell cycle arrest in Detroit 562 cells
Through the assessment of cell cycle changes by flow cytometry after poly(I:C) and cisplatin treatment of Detroit 562 cells, we found that combined poly(I:C) and cisplatin treatment induced a G2/M cell cycle arrest (Fig. 6) . After 72 h we found that 24% of the (untreated) control cells and 45% of the cisplatin and poly(I:C) treated cells were in G2/M phase. This accumulation was found to be further increased by irradiation with 2.5 Gy to 50%. After 72 h 25% of the untreated cells were in S phase, whereas only 15% of the poly(I:C) and cisplatin treated cells were in this phase. We also found that poly(I:C) alone in combination with irradiation led to an increase in the number of cells in G2/M phase.
Discussion
Poly(I:C) is an interesting candidate for the development of novel therapies against cancer, especially in combination with other drugs that may improve the direct apoptotic effects of Fig. 3 Expression of pro-and anti-apoptotic genes after the treatment of HNSCC cells. a SQ20B cells treated with poly(I:C) (10 μg/ml) and cisplatin (1 μM) followed by irradiation. shC-cells transfected with control plasmid, shTLR3-cells transfected with TLR3 plasmid. b Cal27 cells treated with poly(I:C) and cisplatin followed by irradiation. c Detroit 562 cells treated with poly(I:C) and cisplatin followed by irradiation. pIC-poly(I:C), cis-cisplatin. *p < 0.05, **p < 0.01 TLR3 on cancer cells [23] . Here, we have shown that application of poly(I:C) in combination with cisplatin may serve as a strategy for cancer treatment as it can, besides synergistically induce cell death, inhibit the expression of IAP family proteins, in particular c-IAP2 and survivin. Since this is a preclinical study based on cell line experiments, additional in vitro and/or in vivo (animal) studies should be performed to confirm our results.
The combined use of TLR3 activation by poly(I:C) and the application of cisplatin in cancer has been investigated before. We and others have shown that poly(I:C) and cisplatin may act synergistically to induce cancer cell death [17, [23] [24] [25] . A recent study showed that pre-treatment with poly(I:C) increased the amount of cisplatin in the cytoplasm and, by doing so, increased low-dose cisplatin-induced cell death in a TLR3-and caspase-3-dependent manner [23] . Here we uncovered an alternative mechanism by which poly(I:C) and cisplatin may reduce cancer cell survival, i.e., by reducing the expression of survivin and c-IAP2. Survivin belongs to the IAP (inhibitor of apoptosis) family of proteins and is known to inhibit apoptosis mainly via the inhibition of caspases-3 and -7 [26] . Whereas survivin is normally expressed during fetal development and rarely in healthy adult tissues, it has been found to be expressed in various cancers [27, 28] , implying a role in cancer development. One study has shown that poly(I:C) may induce apoptosis of TLR3-expressing Fig. 4 Expression of survivin and c-IAP2 in (a) SQ20B cells after poly(I:C) (10 μg/ml) and cisplatin (1 μM) treatment followed by irradiation. b Detroit 562 cells after poly(I:C) and cisplatin treatment followed by irradiation. c Detroit 562 cells pre-treated with HIF, Myc and MEK inhibitors, treated with poly(I:C) and cisplatin followed by irradiation. pICpoly(I:C), cisPt-cisplatin, HIF-HIF inhibitor, Myc-Myc inhibitor, MEK-MEK inhibitor. Loading control: membrane dyed with amido black and scanned HNSCC cells and that the expression of survivin is downregulated during the process of apoptosis [29] . Contrary to that, we found here that poly(I:C) induced survivin expression, which could subsequently be reduced by cisplatin. Since poly(I:C) can activate TLR3, MDA5 and RIG-I receptors, it may exhibit diverse functions depending on the type of activated receptor.
We also tested the expression of two other pro-apoptotic genes (DIABLO and PUMA) after treatment and found that it was cell-dependent. All cell lines investigated here carry TP53 mutations, but the SQ20B cell line carries a mild intron mutation with no known effect on the protein level. SQ20B was found to exhibit an expression pattern distinct from the Detroit 562 and Cal27 cell lines, which carry non-functional R175H and H193Lp53 mutations, respectively (http://p53.iarc.fr/). The expression of the p53 upregulated modulator of apoptosis (PUMA) gene is regulated by p53 [30] . Its encoded protein inhibits anti-apoptotic proteins (i.e., Mcl-1, Bcl-2, Bcl-XL, Bcl-W and A1) and directly triggers apoptosis mediated by the pro-apoptotic proteins Bax/Bak. It has been reported that loss of PUMA alleles is related to radioresistance [31] and since SQ20B cells are radioresistant [32] , this may explain the downregulation of PUMA after poly(I:C) treatment and the different DIABLO and PUMA gene expression patterns observed in these cells compared to Detroit 562 and Cal27 cells. Cal27 and Detroit 562 cells show increased PUMA expression levels and are more sensitive to irradiation. Diablo (Smac) is an endogenous inhibitor of IAP proteins [33] . We have shown here that poly(I:C) treatment of Detroit 562 cells led to increased c-IAP2 protein levels. Additionally, we found that poly(I:C) treatment led to downregulation of DIABLO while combined poly(I:C) and cisplatin treatment abrogated that effect. This may explain the c-IAP2 expression upregulation observed after poly(I:C) treatment and once again underscores the similarity in the effects of Smac mimetics and the combinatorial poly(I:C) and cisplatin treatment. The differences in survivin expression in Detroit 562 cells at the mRNA and protein levels once more demonstrate the importance of protein expression assessment.
Although we found that apoptosis and ROS formation were increased by poly(I:C) treatment alone and slightly more after combinatorial poly(I:C) and cisplatin treatment, our cell cycle results show that the poly(I:C) and cisplatin combination may represent a more potent therapeutic regimen. We found that poly(I:C) and cisplatin treatment induced G2/M cell cycle arrest in Detroit 562 cells after 72 h. It is well known that the G2/M phase is the most radiosensitive phase, while the S phase is the least radiosensitive phase. We have shown that next to a poly(I:C) and cisplatin induced G2/M arrest, only 15% of the cells stayed in the S phase. This observation implicates that a combined pre-treatment with poly(I:C) and cisplatin renders HNSCC cells sensitive to irradiation.
Radiation therapy may also have immunomodulatory effects. On one hand, radiation therapy may lead to increased Fas expression, which is a trigger of programmed cell death, and to MHC I expression, which is responsible for antigen presentation to cytotoxic CD8-positive lymphocytes [34, 35] . It has been shown that radiation therapy alone can activate CD8-positive lymphocytes through the induction of type I interferons [36] . On the other hand, through the induction of cell death, especially necrosis, radiation may lead to the release of Damage-Associated Molecular Patterns (DAMPs), which also have a dual function. They may either induce immunogenic tumor cell death or contribute to cancer cell survival through chronic inflammation and immunosuppression [37] . The idea of combining TLR3 ligand activation and radiation therapy is based on the premise that TLR3 activation may induce apoptosis of cancer cells and irradiation may stimulate immune responses in addition to inducing cancer cell death through DNA crosslinks and/or breaks. In case of TLR9 and TLR7 agonists, studies have already shown the benefits of their combination with radiotherapy [38] [39] [40] . Kang et al. have shown that activation of TLR3 and 7 may enhance autophagy-induced cell death after radiotherapy of Fig. 6 Cell cycle analysis. Histograms present cell cycle distribution of Detroit 562 cells after poly(I:C) (10 μg/ml) and cisplatin (1 μM) treatment for 24 h (a) and 72 h (b) followed by irradiation (c and d). The flow cytometric histograms are representative of 3 separate experiments and the statistical analysis of each cell cycle phase arrest is presented in section (e). *p < 0.05 breast cancer [41] . Additionally, there are currently two ongoing phase I and I/II clinical trials that are investigating the potential efficacy of co-administration of poly-ICLC and radiotherapy in patients with lymphoma (NCT02061449, NCT01976585) [12] . Aside from radiation therapy-induced direct tumor cell death and enhanced tumor specific immunity, it has been found that irradiation may upregulate programmed death-ligand 1 (PD-L1). The PD-L1/PD-1 axis is known to act as a potent inhibitor of immune activation through inhibition of effector T cell function [42] . Therefore, the combination of radiotherapy with antibodies directed against the PD-L1/PD-1 axis may represent another strategy for the treatment of HNSCC [43, 44] . Others have found that combinations of poly(I:C) with anti-PD-L1 antibodies may inhibit tumor development in several mouse cancer models. This combinatorial therapy also induced a long-lasting protection against tumor re-challenges [45] . Takeda et al. showed very recently that a TLR3-specific ligand (ARNAX), which elicits less cytokine production than poly(I:C), in combination with an anti-PD-L1 antibody and a tumor antigen may overcome PD-1 blockade unresponsiveness and lead to tumor regression without inflammation [46] . Therefore, the use of TLR3 agonist in combination with radiotherapy or PD-1/PD-L1 inhibitors may induce multiple beneficial effects during cancer treatment.
We conclude that the combinatorial use of poly(I:C), cisplatin and radiotherapy may serve as a valid strategy for the treatment of HNSCC. This conclusion is primarily based on the induction of a reduced cell survival, a reduced survivin and c-IAP expression, an increased PUMA and DIABLO expression (depending on the cell line used), an increased ROS generation and an increased G2/M cell cycle arrest.
